The Compounded Semaglutide Crackdown, Explained for Affiliates

What made compounded GLP-1s legal to sell in the first place?

A federal drug-shortage listing created the opening, not a gap in the underlying law. Once FDA listed injectable semaglutide and tirzepatide as drugs in shortage, section 503A pharmacies and section 503B outsourcing facilities could compound essentially-copy versions under the agency's enforcement-discretion policy, filling gaps left by constrained branded supply. That policy was conditional by design: enforcement discretion applies only while the shortage designation holds, and FDA said so from the start.

A second, narrower path ran alongside the shortage exception: personalized dosing. Under 21 U.S.C. 353a(b)(2), a change made 'for an identified individual patient' that produces 'a significant difference, as determined by the prescribing practitioner' escapes the essentially-a-copy rule that would otherwise bar compounding a drug that duplicates an approved product. Section 353b(d)(2)(B) uses different wording again, requiring 'a clinical difference' patient by patient — a prescriber-documented showing, not a standing menu of doses sold at volume.

Peptides with no approved counterpart never had either path available. FDA states plainly that retatrutide and cagrilintide 'cannot be used in compounding under federal law' because neither is a component of an FDA-approved drug and neither has been found safe and effective for any condition — meaning any 2025-2026 offer selling retatrutide for human weight loss sat outside the shortage exception from day one.

What changed when regulators declared the shortage over?

Regulators declared the shortage over on two separate dates, and each one started a countdown. FDA determined the tirzepatide injection shortage resolved on December 19, 2024, after an earlier October 2024 determination was remanded for reevaluation in litigation, and determined the semaglutide injection shortage resolved on February 21, 2025.

The wind-down clock then ran out. FDA's enforcement-discretion period for compounding tirzepatide ended February 18, 2025, for 503A pharmacies and physicians, and March 19, 2025, for 503B outsourcing facilities; the parallel dates for semaglutide were April 22, 2025, and May 22, 2025. All four deadlines have now lapsed, and FDA states neither drug currently appears on the 503B bulks list or the agency's drug shortage list.

Most operators treat the compounding window as permanently closed, and the practical reality supports that. But the legal question underneath it is not fully settled: compounders lost the request for a preliminary injunction twice, first on tirzepatide in March 2025 and then on semaglutide in April 2025, and the semaglutide case is now on appeal to the Fifth Circuit as Outsourcing Facilities Association v. FDA, No. 25-10758, with Novo Nordisk as intervenor. A denied preliminary injunction is not a final ruling on the merits, so the door is narrower than 'closed for good' implies.

Which offer types disappeared, and which absorbed the demand?

The offers that disappeared were the ones selling a compounded copy of a branded drug at scale — semaglutide or tirzepatide injections marketed as interchangeable with Wegovy, Ozempic, Mounjaro or Zepbound. Demand for those did not vanish; it split three ways, toward branded telehealth access, toward personalized-dosing programs that can document an individual clinical difference, and toward peptides with no approved counterpart to compare against.

Operators tracking which weight-loss angle still converts run the same due diligence they would apply before switching any offer, checking payout terms the way they would cross-check Digistore24's marketplace stats before committing spend to a new vertical.

Some of that demand moved to international telehealth networks that pay out through Hotmart rather than US-based processors, where Hotmart's payout terms for international affiliates end up mattering more to campaign economics than the underlying compounding law, since a network's payment terms don't change just because a drug's shortage status did.

Retatrutide absorbed a disproportionate share of the migrated demand, largely because Eli Lilly's Phase 3 TRIUMPH program reported strong results — TRIUMPH-1 showed roughly 28% to 30% average weight loss at 80 weeks on the 12 mg dose, with a marketing application anticipated around Q1 2027. None of that changes the legal status today: every US sale of retatrutide for human use in 2026 is the sale of an unapproved new drug, trial results notwithstanding.

What does the crackdown signal about telehealth offer risk generally?

The crackdown signals that FDA now treats marketing context as the classification test, not the disclaimer printed on the label. In a March 31, 2026 warning letter to Gram Peptides, FDA wrote that despite 'Research Use Only' and 'not intended for human consumption' labeling, mechanism-of-action and weight-loss copy on the company's product pages established that the products were 'intended to be drugs for human use' under the intended-use rule at 21 CFR 201.128.

Telehealth intermediaries are squarely in scope, not just compounders. On March 3, 2026, FDA announced 30 warning letters to telehealth companies over claims implying sameness with FDA-approved products and over ads that obscured product sourcing behind a telehealth brand's own name. A month earlier, Commissioner Marty Makary named Hims & Hers among companies that, he said, cannot claim compounded products 'are the same as drugs approved by FDA.'

The adverse-event count gives a rough sense of scale, and it is likely an undercount. FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide as of May 31, 2026, a figure the agency itself flags as underreported because state-licensed 503A pharmacies face no federal requirement to submit them.

Can affiliates still promote anything compounder-adjacent safely?

Yes, but the safe territory is narrower than most affiliates assume, and it sits outside the compounded-injectable category entirely. Topical peptide cosmetics stay lawful while claims stay at the appearance level — FDA draws the line at 'moisturizing the skin' versus claims to 'increase the skin's production of collagen.' Oral NMN and NR supplements are back on solid statutory footing after FDA reversed its 2022 position in September 2025, though an NDI notification is still required. For the injectable category specifically, our breakdown of what's still legal in compounded GLP-1 offers now that the shortage is over covers the state-by-state variation.

A disclaimer does not rescue a claim that contradicts it. FTC's own guidance makes the point with an acne app that carried an 'entertainment purposes only' disclaimer alongside a treatment claim; FTC called the disclaimer 'directly contradictory and ineffective.' FDA applies the identical logic to 'research use only' labels sitting next to dosing instructions, and to supplement copy that names a prescription GLP-1 drug — doing so is itself treated as evidence of a disease claim under 21 CFR 101.93(g)(2).

State enforcement moves faster than federal warning letters, and it can end a business in weeks. Alabama's attorney general sued Aurora IV and Wellness in November 2025 for injecting patients with material labeled for laboratory research only, won a TRO that closed the clinic immediately, and settled in January 2026 for roughly $24,000 in damages and a surrendered nursing license. Connecticut's attorney general has pursued similar conduct under a corporate-practice-of-medicine theory rather than a drug-labeling one.

How did the crackdown reshape weight-loss ad spend?

Weight-loss ad spend did not shrink so much as it re-routed toward advertisers who can clear a certification bar. Meta restricts prescription-drug ads to online pharmacies, telehealth providers and manufacturers holding active LegitScript certification, and caps targeting to the United States, Canada and New Zealand — a gate that excludes most compounded-injectable sellers outright.

Google runs a parallel gate: online pharmacies need LegitScript or NABP accreditation, telemedicine providers need LegitScript, and both need separate certification with Google itself before they can keyword-target a list that names semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro and Zepbound explicitly. TikTok treats supplements as a restricted rather than prohibited industry, requiring per-market licenses across Southeast and Northeast Asia and banning them outright in Japan, the Philippines and Lebanon — a patchwork that pushes global campaigns toward whichever market has the loosest paperwork, tracked by tools like a TikTok ad spy tool.

Meta also folded its old standalone circumvention policy into the broader Account Integrity standard in 2025-2026, which is the same enforcement area that now catches accounts built to route reviewers away from the real landing page — the same category of risk a cloaker exists to manage on the creative side, and one platforms treat as an asset-level violation rather than a single rejected ad.

Which early signs would flag the next enforcement wave?

The clearest early signal is procedural, not enforcement: watch the bulks-list dockets before watching for warning letters. FDA's proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list closed its public comment period on June 29, 2026, and the agency has not yet issued a final determination — that determination, whenever it lands, will set the template for the next drug class.

• A second Pharmacy Compounding Advisory Committee meeting, expected in February 2027, will cover five more peptides plus injectable GHK-Cu — a preview of which substances face the fight BPC-157 just went through
• Rising adverse-event report counts, even acknowledged as an undercount, tend to precede warning-letter waves rather than follow them
• FDA has said it sent more misleading-ad warning letters in six months than in the entire preceding decade, so a sudden jump in letter volume for a new category is itself the signal, not a side effect
• State corporate-practice-of-medicine laws taking effect on staggered dates — Oregon's SB 951 from January 2026, California's SB 351 from January 2026 — extend enforcement risk to clinic ownership structures, not just the product being sold

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

When the topic touches health claims, platform policy, or GLP-1 market research, validate the observable campaign signals against primary references such as FDA human drug compounding, FTC health claims guidance, and Meta advertising standards. Daily Intel adds the proprietary direct-response layer by mapping how those rules show up in active VSLs, Meta creatives, funnels, transcripts, UTMs, and checkout paths.

For deeper evaluation, continue through Daily Intel research methodology, Facebook Ad Library Impressions: The New Spend Signal, First Sale on an Ad: When One Conversion Means Scale, Does Raising Budget Reset the Learning Phase? The Rules, Como Ler UTMs de Concorrentes e Encontrar a Campanha, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.